Markers that can discriminate between indolent and aggressive prostate tumours are needed. We studied gene methylation in non-neoplastic tissue adjacent to prostate tumour (NTAT) in association with prostate cancer mortality.From two cohorts of consecutive prostate cancer patients diagnosed at one pathology ward in Turin, Italy, we selected 157 patients with available NTAT and followed them up for more than 14 years. We obtained DNA from NTAT in paraffin-embedded prostate tumour tissues and used probe real-time PCR to analyse methylation of the glutathione S-transferase (GSTP1) and adenomatous polyposis coli (APC) gene promoters.Prevalence of APC and GSTP1 methylation in the NTAT was between 40 and 45%. It was associated with methylation in...
<div><p>Background</p><p>Prostate cancer (PCa) is a very heterogeneous disease with respect to clini...
Altered genome methylation is a hallmark of human malignancies. In this study, high-throughput analy...
Prostate cancer is a highly prevalent malignancy, which is clinically silent but curable while organ...
Markers that can discriminate between indolent and aggressive prostate tumours are needed. We studie...
Prostate cancer (PCa) is a very heterogeneous disease with respect to clinical outcome. This study e...
GSTP1 belongs to the GSTs family, a group of enzymes involved in detoxification of exogenous substan...
In DNA from prostate tumors, methylation patterns in gene promoter regions can be a biomarker for di...
Aberrant promoter methylation is known to silence tumor-suppressor genes in prostate cancer. Using a...
Aberrant promoter methylation is known to silence tumor-suppressor genes in prostate cancer. Using a...
BACKGROUND Prostate cancer (PCa) is a very heterogeneous disease with respect to clinical outcome...
In DNA from prostate tumors, methylation patterns in gene promoter regions can be a biomarker for di...
OBJECTIVE: Prostate Specific Antigen (PSA) is a commonly used marker for the diagnosis and follow-up...
DNA methylation alterations as a result of field cancerization may be used as diagnostic biomarkers ...
DNA methylation alterations as a result of field cancerization may be used as diagnostic biomarkers ...
<div><p>Many differentially methylated genes have been identified in prostate cancer (PCa), primaril...
<div><p>Background</p><p>Prostate cancer (PCa) is a very heterogeneous disease with respect to clini...
Altered genome methylation is a hallmark of human malignancies. In this study, high-throughput analy...
Prostate cancer is a highly prevalent malignancy, which is clinically silent but curable while organ...
Markers that can discriminate between indolent and aggressive prostate tumours are needed. We studie...
Prostate cancer (PCa) is a very heterogeneous disease with respect to clinical outcome. This study e...
GSTP1 belongs to the GSTs family, a group of enzymes involved in detoxification of exogenous substan...
In DNA from prostate tumors, methylation patterns in gene promoter regions can be a biomarker for di...
Aberrant promoter methylation is known to silence tumor-suppressor genes in prostate cancer. Using a...
Aberrant promoter methylation is known to silence tumor-suppressor genes in prostate cancer. Using a...
BACKGROUND Prostate cancer (PCa) is a very heterogeneous disease with respect to clinical outcome...
In DNA from prostate tumors, methylation patterns in gene promoter regions can be a biomarker for di...
OBJECTIVE: Prostate Specific Antigen (PSA) is a commonly used marker for the diagnosis and follow-up...
DNA methylation alterations as a result of field cancerization may be used as diagnostic biomarkers ...
DNA methylation alterations as a result of field cancerization may be used as diagnostic biomarkers ...
<div><p>Many differentially methylated genes have been identified in prostate cancer (PCa), primaril...
<div><p>Background</p><p>Prostate cancer (PCa) is a very heterogeneous disease with respect to clini...
Altered genome methylation is a hallmark of human malignancies. In this study, high-throughput analy...
Prostate cancer is a highly prevalent malignancy, which is clinically silent but curable while organ...